RNA vaccines

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Retrieved on: 
Tuesday, July 20, 2021

The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.

Key Points: 
  • The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.
  • The data suggest a single, adjuvant-free, needle-free intranasal dose of MV-014-212 may provide broad immunity to protect against infection by SARS-CoV-2 and its variants.
  • In NHPs, Meissas intranasal COVID-19 vaccine generated both mucosal and systemic antibodies and was highly protective against wild-type SARS-CoV-2 challenge.
  • We believe Meissas intranasal COVID-19 vaccine has the potential to be an important part of the endgame solution to contain SARS-CoV-2.

SVMHS Helps Vaccinate Indigenous Population

Retrieved on: 
Friday, July 16, 2021

In June, SVMHS partnered with Centro Binacional para el Desarollo Indigena Oaxaqueno (CBDIO) to deliver free COVID-19 vaccine to underserved populations.

Key Points: 
  • In June, SVMHS partnered with Centro Binacional para el Desarollo Indigena Oaxaqueno (CBDIO) to deliver free COVID-19 vaccine to underserved populations.
  • The Center identified Greenfield as a vulnerable community needing easy access to the vaccine and the convenience of the SVMHS Mobile Health Clinic.
  • Our partnerships with grass roots organizations serving indigenous populations are more important than ever before."
  • SVMHS Mobile Health Clinic staff deliver COVID-19 Pfizer first doses to Greenfield residents at a special vaccine clinic on June 26.

Novel Saliva Assay by Accure Health Tracks COVID-19 Vaccine Response in Proof-of-Concept Study

Retrieved on: 
Thursday, July 15, 2021

Accure Health , a developer of rapid digital diagnostics, today announced the online publication of preliminary data showing that its novel saliva assay can assess individual immune response to COVID-19 vaccines, monitor neutralizing antibody levels over time, and model immune protection against SARS-Cov-2 variants.

Key Points: 
  • Accure Health , a developer of rapid digital diagnostics, today announced the online publication of preliminary data showing that its novel saliva assay can assess individual immune response to COVID-19 vaccines, monitor neutralizing antibody levels over time, and model immune protection against SARS-Cov-2 variants.
  • In a pilot study involving 111 participants, Accure Health demonstrated the potential of its TiMES digital platform and TiMES-Now assay in monitoring the neutralizing antibody levels against SARS-CoV-2 in saliva samples.
  • Critical questions such as the durability of COVID-19 immunity or the clinical efficacy of vaccines require large datasets to generate meaningful insights.
  • Accure Health has active collaborations with the Massachusetts General Hospital, and PATH, among others.

Researchers to investigate vaccine uptake, efficacy and side effects in vulnerable urban populations

Retrieved on: 
Wednesday, July 14, 2021

The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is investing approximately $770,000 in a new study that will investigate the uptake, effectiveness, and side effects of COVID-19 vaccines among members of vulnerable urban populations in Canada.

Key Points: 
  • The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is investing approximately $770,000 in a new study that will investigate the uptake, effectiveness, and side effects of COVID-19 vaccines among members of vulnerable urban populations in Canada.
  • Researchers will recruit more than 250 people who use drugs from three community-recruited cohorts in Vancouver, British Columbia.
  • Following their first visit, researchers aim to assess vaccine uptake, adherence to vaccination protocols, as well as monitor and investigate potential side effects of the vaccines.
  • Researchers will also analyze the effectiveness of the SARS-CoV-2 vaccines and compare their effectiveness among subgroups of vulnerable populations.

BurstIQ & FlowMetric Life Sciences Partner to develop VaxEffect™, a diagnostic Platform for COVID-19 Immune Response Testing

Retrieved on: 
Wednesday, July 14, 2021

DENVER, July 14, 2021 /PRNewswire/ -- BurstIQ , the leading provider of blockchain enabled data exchange solutions, announced today that longtime partner FlowMetric Life Sciences , launched their novel vaccine immune response test, VaxEffect.

Key Points: 
  • DENVER, July 14, 2021 /PRNewswire/ -- BurstIQ , the leading provider of blockchain enabled data exchange solutions, announced today that longtime partner FlowMetric Life Sciences , launched their novel vaccine immune response test, VaxEffect.
  • "The goal of the collaboration with BurstIQ was to bring the VaxEffect COVID-19 vaccine immune response test and powerful personalized results to health care providers and their patients.
  • BurstIQ is the leading provider of blockchain-enabled data solutions for the identity, healthcare and life sciences industries.
  • The experienced team of scientists at FlowMetric Diagnostics, a division of FlowMetric Life Sciences Inc. (FlowMetric), has introduced VaxEffect, the world's first COVID-19 vaccine immune response test built upon superior Flow Cytometry technology.

Government of Canada funds five new projects to encourage COVID-19 vaccination in Canada

Retrieved on: 
Monday, July 12, 2021

This project will provide credible COVID-19 vaccine information to these communities and deliver low-barrier vaccine clinics and mobile services.

Key Points: 
  • This project will provide credible COVID-19 vaccine information to these communities and deliver low-barrier vaccine clinics and mobile services.
  • This project will provide COVID-19 testing and vaccine education, promotion, and outreach to facilitate and encourage vaccine uptake among these populations.
  • In 2020, as a response to Canada's COVID-19 vaccination efforts and building on the early momentum of the IPF, the Government of Canada invested an additional $64 million for projects to support COVID-19 vaccine uptake in Canada.
  • Regina Treaty/Status Indian Services Inc. will receive up to $100,000 for its project, Regina Urban Indigenous COVID-19 Vaccination Strategy.

Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine

Retrieved on: 
Monday, July 12, 2021

We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
  • Moderna has filed for emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adolescents with global health agencies.

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

Retrieved on: 
Wednesday, July 7, 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Companys quadrivalent seasonal influenza mRNA vaccine candidate.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Companys quadrivalent seasonal influenza mRNA vaccine candidate.
  • This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of mRNA-1010, Modernas seasonal influenza vaccine candidate in healthy adults 18 years and older in the U.S.
  • We are pleased to have begun this Phase 1/2 study of mRNA-1010, our first mRNA seasonal flu vaccine candidate to enter the clinic.
  • We expect that our seasonal influenza vaccine candidates will be an important component of our future combination respiratory vaccines, said Stphane Bancel, Chief Executive Officer of Moderna.

Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency

Retrieved on: 
Thursday, July 1, 2021

France is at the heart of European innovation in healthcare and will play an important role in Modernas strategic growth plan.

Key Points: 
  • France is at the heart of European innovation in healthcare and will play an important role in Modernas strategic growth plan.
  • Our collaboration with Moderna has created a strong foundation for vaccine production in France, leveraging our manufacturing excellence to ensure the timely delivery of the Moderna COVID-19 vaccine to Europe, said Marc Funk, CEO of Recipharm.
  • Modernas partnership with Recipharm is reflective of the Companys commitment to expanding its global manufacturing capacity.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.

Melbourne, Australia Develops Next-Generation mRNA COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, July 1, 2021

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the States mRNA manufacturing and research capability announced that a locally-developed COVID vaccine candidate will enter Phase 1 clinical trials in October, 2021.

Key Points: 
  • mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the States mRNA manufacturing and research capability announced that a locally-developed COVID vaccine candidate will enter Phase 1 clinical trials in October, 2021.
  • mRNA Victoria will fund the Monash Institute of Pharmaceutical Sciences (MIPS) to manufacture doses of the mRNA COVID-19 vaccine for trials, establishing Australias first manufacturing capability of mRNA vaccines.
  • While mRNA Victoria is charged with building Victorias mRNA manufacturing capability to fast-track Australias future supply of coronavirus vaccines, there are wider-ranging implications to its mission.
  • Australias first locally-developed mRNA COVID-19 vaccine candidate is a collaboration between MIPS and the Peter Doherty Institute for Infection and Immunity (Doherty Institute), reflecting the strong mRNA research sector in Victoria and leading the national charge to develop mRNA manufacturing capability.